Immuno 2026 Day 6 Highlights: Dose Optimization and Better Research Decisions
Teva Receives U.S. FDA Approval for Denosumab Biosimilar for Oncology Indications
EVOLUTE: Enfortumab Vedotin in Older Patients With Advanced Urothelial Carcinoma
Deulorlatinib in ALK-Positive NSCLC: Can Deuteration Improve on Lorlatinib?
Radiotherapy for R/R Hodgkin Lymphoma: Targeting Residual Disease After BV and PD-1 Blockade
A New Era in Cervical Cancer Prevention in Algeria: Integration of HPV Vaccination into the National Immunization Program
Pfizer to Present 45 Abstracts at ESMO 2026, With Data in Breast, Genitourinary, Lung Cancers and Melanoma
